tbuckley/cabot-search huggingface dataset:
AB0556 ESR/C3 and Lymphocyte/ESR Ratios – Markers of Disease Activity in Systemic Lupus Erythematosus
Authors: C. Delcea, A. Dima, S. Caraiola, C. Jurcut, C. Badea, E. Balanescu, D. Nitescu, A. Nicolau, R. Ionescu, C. Baicus, G.A. Dan
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), C3 complement (C3), and lymphocyte count are markers of disease activity in patients with systemic lupus erythematosus (SLE). <h3>Objectives</h3> Our aim was to identify a prediction tool for SLE disease activity with increased accuracy by combining the afore mentioned parameters, two by two, as ratios. <h3>Methods</h3> We prospectively enrolled 130 SLE patients admitted consecutively to our department. Clinical and biological parameters were assessed in each patient. Disease activity was quantified using Systemic Lupus Activity Measure (SLAM) and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). For each patient we analyzed ESR/C3, CRP/C3, lymphocyte/ESR and lymphocyte/CRP ratios. <h3>Results</h3> The mean age of our study group was 46.58±12.69 years old and 90% were female. SLAM was correlated with ESR/C3 (r=0.549, p&lt;0.01), CRP/C3 (r=0.343, p&lt;0.01) and lymphocyte/ESR ratios (r=-0.240, p=0.01) better than with ESR (r=0.486, p&lt;0.01), CRP (r=0.229, p=0.02), C3 (r=0.175, p=ns) and lymphocyte number (r=-0.235, p=0.01) alone. SLEDAI was correlated with ESR/C3 (r=0.745, p&lt;0.01), CRP/C3 (r=0.342, p&lt;0.01) and lymphocyte/ESR ratios (r=-0.312, p&lt;0.01) better than with ESR (r=0.663, p&lt;0.01), CRP (r=0.235, p=0.01) and lymphocyte number (r=-0.324, p&lt;0.01) alone. In ROC curve analysis, ESR/C3 ratio predicted SLEDAI&gt;10 with an AUC of 0.779, p&lt;0.01 similar to ESR (AUC 0.782, p&lt;0.01) and SLAM&gt;10 with an AUC of 0.821, p&lt;0.01 less than ESR (AUC 0.909, p&lt;0.01). Lymphocyte/ESR ratio predicted SLEDAI&gt;10 with an AUC of 0.754, p&lt;0.01 and SLAM&gt;10 with an AUC of 0.929, p&lt;0.01. ESR/C3 ratio was the best predictor for severe disease quantified as SLAM&gt;20 with an AUC 0.998 (p&lt;0.01) compared to the lymphocyte/ESR ratio (AUC 0.983, p&lt;0.01) and ESR (AUC 0.974, p&lt;0.01). Lymphocyte/ESR ratio (AUC 0.890, p&lt;0.01) and ESR (AUC 0.886, p&lt;0.01) were better to predict severe disease using SLEDAI&gt;20 compared to ESR/C3 ratio (AUC 0.850, p&lt;0.01). <h3>Conclusions</h3> Lymphocyte/ESR and ESR/C3 ratios correlate with disease activity in SLE patients, possibly with higher accuracy compared to ESR, C3 and lymphocyte number alone. <h3>Acknowledgements</h3> This paper is supported by POSDRU/159/1.5/S/137390. <h3>Disclosure of Interest</h3> None declared
SAT0141 Safety of Anti-TNFS in RA Patients in Real Life: Results from a Systematic Litterature Review and Meta-Analyses from Biologic Registers
Authors: M. De la Forest, J. Brugneaux, G. Utard, C. Salliot
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In daily practice safety in rheumatoid arthritis (RA) patients receiving biological treatment is an important issue. Unlike randomized controlled trials, biologic registers provide real life safety data. <h3>Objectives</h3> To identify biologic registers worlwide, to collect and analyze data regarding safety in RA patients under anti-TNF treatments. <h3>Methods</h3> Up to December 2014 and according the Cochrane Collaboration Guidelines, systematic review was performed independently by 2 rheumatologists using PUBMED, EMBASE and Cochrane library databases. Worldwide biologic registers were identified and publications regarding safety issues in RA patients were included (mortality, cardiovascular events, cancer including lymphoma and melanoma and serious infections). Fixed-effect meta-analyses were performed to compare safety events between 1) biological agent and non biological DMARD (nbDMARD), 2) anti-TNFs. Pooled odds ratios (ORs) were calculated, using the Mantel–Haenszel method with a continuity correction. <h3>Results</h3> 43 biological registers were identified wordwide corresponding to 322 publications in PUBMED and EMBASE. From 114 publications on safety in RA patients receiving anti-TNF, 40 were included for meta-analyses. Compared to nbDMARD, mortality and cardiovascular events were significantly descreased in patients treated with anti-TNFs (OR=0.77 [95%CI 0.70-0.85] and OR=0.60 [0.51-0.71]), respectively). Anti-TNFs did not increase the risk of cancer in patients without or with prior malignancy (OR=0.70 [0.64-0.75] and OR=0.81 [0.42-1.55], respectively), lymphoma (OR=0.87 [0.65-1.16]) and melanoma (OR=2.46 [0.70-8.65]). As expected, serious infections were significantly increased during anti-TNF treatment (OR=1.60 [1.47-1.75]) compared to nbDMARD. Soluble receptor to TNF (etanercept) would lead to less serious infections than infliximab (OR=0.82 [0.73-0.92]), without significant difference compared to adalimumab (OR=1.22 [1.08-1.37]). <h3>Conclusions</h3> By reducing dramatically chronique inflammation in RA patients, anti-TNFs descrease mortality, cardiovascular events without increase significantly the risk of cancer, compared to nbDMARDs. <h3>Disclosure of Interest</h3> None declared
Rhodanese Activity of Resting, Regenerating, and Neoplastic Liver Tissue of the Rat&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Otto Rosenthal
Journal: JNCI Journal of the National Cancer Institute (1955)

Rhodanese Activity of Resting, Regenerating, and Neoplastic Liver Tissue of the Rat, Get access Otto Rosenthal Otto Rosenthal Harrison Department of Surgical Research, Schools of Medicine, University of Pennsylvania, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1611–1614, https://doi.org/10.1093/jnci/15.Supplement_5.1611 Published: 01 April 1955
Lung-Cancer Staging with PET–CT
Authors: Jung-Jyh Hung, Wen-Juei Jeng, Jung-Sen Liu
Journal: New England Journal of Medicine (2009)

To the Editor: In their assessment of the usefulness of combined positron-emission tomography and computed tomography (PET–CT) in the preoperative staging of lung cancer, Fischer et al. (July 2 issue)1 provide no information on the interval between baseline staging and thoracotomy, nor on the use of neoadjuvant therapy. A prolonged delay between PET–CT and surgery may negate the diagnostic value of PET–CT and may be due to coexisting conditions that would themselves have a negative effect on survival. Although the PET–CT scans in the study were read by an experienced radiologist and a nuclear medicine specialist, it is unclear who interpreted the diagnostic CT scans and whether the final tumor–node–metastasis (TNM) stage was determined by the same investigators in all patients or whether the stage was decided locally. These factors are important for assessing the influence of observer bias on the study results.
FRI0452 Predictors of Pulmonary Arterial Hypertension in 79 Patients with Mixed Connective Tissue Disease
Authors: A. Felis-Giemza, E. Kontny, E.N. Haładyj, A. Rowinska-Osuch, K. Walkiewicz-Pielaszek, Z. Czuszynska, Z. Zdrojewski, A. Paradowska-Gorycka, M. Olesinska
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Pulmonary arterial hypertension (PAH) is the predominant cause of morbidity and mortality in mixed connective tissue disease (MCTD). PAH is characterized by the thickening of the small arteries, arterioles of the lungs, development of plexiform lesions, arteritis and intima media hypertrophy. The incidence of PAH in MCTD is estimated between 20% and 30%<sup>1-3</sup>. <h3>Objectives</h3> The aim of the study was to estimate the prevalence of PAH in a cohort of MCTD patients and to search for clinical and immunological predictors of this complication presence. <h3>Methods</h3> The study included patients, who fulfilled with Alarcon-Segovia and Kasukawa sets of criteria for MCTD. Clinical features of MCTD, autoantibody profile and serum concentrations of IL-1, IL-10, IL-21, IL-23, TNFα, IFNγ, VEGF were assessed. Transthoracic echocardiography (TTE) was performed in all patients to estimate the pulmonary artery pressures. PAH was defined as systolic pulmonary artery pressure (sPAP) ≥36 mmHg according to current guidelines. The study group consisted of 79 patients with MCTD, including 66 (83.5%) women. The median age of patients at the time of the study was 44 years (18-67). <h3>Results</h3> 12 patients (15.2%) developed PAH. PAH was statistically significantly more frequent in men, older patients and patients with first MCTD symptoms after 40 years of age. PAH more often developed in patients with BMI&gt;25 and hypertension. The most common serological abnormality, observed in all patients with PAH but only in 51 patients without this complication (100% vs 76%) was the presence of anti-U1-RNP-C antibodies. Among cytokines only reduced serum levels of TNF-α (28,47 vs 39,68 pg/ml) correlated with PAH. Patients with high disease activity (ILD, vasculitis, neuropathy, renal involvement, arthritis, serositis, myositis, puffy hands and skin lesions) were more prone to develop PAH than patients with mild disease (14,75 vs 8,7). <h3>Conclusions</h3> The study showed some clinical correlations of PAH (male gender, BMI &gt;25, hypertension and anti-U1-RNP-C antibodies, low serum levels of TNF-α) that could be useful in defining the patient9s profile prone to develop this severe complication. Identifying a subgroup of patients in a risk of development of PAH allows further to applicate early adequate treatment. <h3>Acknowledgements</h3> 1 Prakash UBS. Respiratory complication in mixed connective tissue disease. Clin Chest Med 1998;19:733–46. 2 Burdt MA, Hoffman RW, Deutscher SL et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899–909. 3 Prakash UBS. Pulmonary manifestations in mixed connective tissue disease. Semin Resp Med 1988;9:318–24. <h3>Disclosure of Interest</h3> None declared
Cancer Follow-up
Authors: O Scheibe
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHRONIC ULCERATIVE COLITIS
Authors: J B O'LEARY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conceptual short-term memory (CSTM) supports core claims of Christiansen and Chater
Authors: Mary C Potter
Journal: Behavioral and Brain Sciences (2016)

Abstract Rapid serial visual presentation (RSVP) of words or pictured scenes provides evidence for a large-capacity conceptual short-term memory (CSTM) that momentarily provides rich associated material from long-term memory, permitting rapid chunking (Potter 1993; 2009; 2012). In perception of scenes as well as language comprehension, we make use of knowledge that briefly exceeds the supposed limits of working memory.
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors
Authors: JE Anderson, FR Appelbaum, G Schoch, T Gooley, C Anasetti, WI Bensinger, E Bryant, CD Buckner, TR Chauncey, RA Clift, K Doney, M Flowers, JA Hansen, PJ Martin, DC Matthews, JE Sanders, H Shulman, KM Sullivan, RP Witherspoon, R Storb
Journal: Blood (1996)
The psychiatric emergency service holding area: effect on utilization of inpatient resources
Authors: P M Gillig, J R Hillard, J Bell, H E Combs, C Martin, J A Deddens
Journal: American Journal of Psychiatry (1989)

This study compared the rates of hospitalization from two psychiatric emergency services which were similar except that one service had an extended evaluation unit, or holding area, allowing up to 24 hours of evaluation. The rate of hospitalization from the service with the extended evaluation unit was 36%; the rate from the other service was 52%. The difference in admission rates was related to the availability of the extended evaluation unit, which made it possible for many patients to avoid rather than merely postpone admission to the hospital. Clinical determinants of admission and of successful treatment in the unit were also reviewed.
SAT0308 Tophus Resolution with Pegloticase – A Prospective Dual Energy Computed Tomography Study
Authors: G. Schett, E. Araujo, S. Bayat, C. Petsch, M. Englbrecht, F. Faustini, A. Kleyer, A. Hueber, A. Cavallaro, M. Lell, N. Dalbeth, B. Manger, J. Rech
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Refractory gout is a serious medical condition, which leads to massive deposition of uric acid crystals in the body resulting in the formation of tophi. A new highly effective treatment modality based on the administration of recombinant PEGylated uricase (pegloticase) allows to approach such patients. Pegloticase cleaves uric acid and leads to a profound drop in serum uric acide levels. How this decrease in uric acid in the body affects the resolution of existing tophi is not yet adequately characterized. <h3>Objectives</h3> To investigate the effect of intensive lowering of serum uric acid levels by pegloticase on the resolution of tophi in patients with refractory gout. <h3>Methods</h3> Descriptive study in patients with refractory gout receiving pegloticase treatment. Serum uric acid levels were measured before and after each infusion. Dual energy computed tomography scans were taken from all patients before the first infusion and after the last infusion. Computerized tophus volumes were calculated for the baseline and follow up assessments and compared with each other. <h3>Results</h3> Ten patients with refractory gout and baseline mean serum uric acid level of 8.1 mg/dL were enrolled. Pegloticase effectively reduced tophi in all patients showing a decrease in volume by 71.4%. Responders, showing reduction of serum uric acid level below 6 mg/dl during at least 80% of the treatment time, were virtually cleared from tophi (-94.8%). Dependent on their anatomical localization, resolution of tophi showed different dynamics, with articular tophi showing fast and tendon tophi slow resolution. <h3>Conclusions</h3> Tophi are highly sensitive to pegloticase treatment, particularly when located at articular sites. Debulking of disease and a tophus-free state can be reached within a few months of pegloticase treatment. DECT allows for comprehensively assessing tophus burden and monitoring treatment responses. <h3>Disclosure of Interest</h3> None declared
Minced beef and human salmonellosis: review of the investigation of three outbreaks in France
Authors: S Haeghebaert, L Duché, C Gilles, B Masini, M Dubreuil, J- C Minet, P Bouvet, F Grimont, E Delarocque Astagneau, V Vaillant
Journal: Eurosurveillance (2001)

The synthesis of investigations of three salmonellosis outbreaks which occured in France between 1998 and 2000 confirms the role of the consumption of minced beef and highlights the importance of prevention measures.
AB1142 Epidemiology and Outcome of Adult-Onset still's Disease in Northwestern Thrace Region in Turkey
Authors: M.A. Balci, O.N. Pamuk, G.E. Pamuk, F.K. Uzundere, S. Donmez
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Adult-onset Still9s disease (AOSD) is an inflammatory disease characterized by fever, arthritis and typical, salmon-colored rash which is more pronounced and is accompanied by increased fever at nights. Currently, there is limited data on the prevalence of AOSD.Currently, there is limited data on the frequency of AOSD. Studies based on questionnaire data have reported an annual AOSD incidence of 0.22/100,000 in Japan [1] and 0.16/100,000 in France [2]. A study using hospital-based database has found an annual AOSD incidence of 0.4/100,000 in Northern Norway [3]. <h3>Objectives</h3> In our study, we aimed to determine the epidemiology, general clinical features and outcomes of AOSD on the basis of hospital-based data in Thrace, the northwestern region of Turkey. We also evaluated other epidemiological studies and major series as a systematic review. <h3>Methods</h3> Patients diagnosed with AOSD at the Rheumatology Department of the Medical Faculty of Trakya University between 2003 and 2014 were reviewed retrospectively. Patients9 clinical features, laboratory measurements, demographics, received treatments, follow-up durations, disease courses, outcomes and complications were evaluated. <h3>Results</h3> Our study included 42 patients with AOSD. Of them, 32 (76.2%) were females and 10 (23.8%) were males (female to male ratio: 3.2). Over the course of the study, the annual incidence of AOSD was 0.62/100,000 and the overall prevalence was 6.77/100,000. The most common findings were fever (97.6%), arthralgia (95.2%), arthritis (76.2%), rash (73.8%) and sore throat (40.5%). <h3>Conclusions</h3> In conclusion, in our hospital-based study on AOSD as a condition with very limited epidemiological data, AOSD frequency was significantly higher compared to other series. Female gender was more common in our series with predominantly monocyclic pattern in relation to follow-up period compared to other series. <h3>References</h3> Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated 2010;89:37–46.prevalence and incidence of adult Still9s disease: findings by a nationwide epidemi-ological survey in Japan. J Epidemiol 1997;7:221–5. Still9s disease. Scand J Rheumatol 2003;32:119–21. Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still9s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995; 54:587. Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still9s disease in [42] Behrens EM. Macrophage activation syndrome in rheumatic disease: what is theNorthern Norway. Scand J Rheumatol 2006;35:48–51. <h3>Disclosure of Interest</h3> None declared
Cryotherapy—As Ancient as the Pharaohs
Authors: Eric Maranda, Brian J. Simmons, Paolo Romanelli
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Case 4-1965
Authors: Rita M. Kelley, Robert E. Scully
Journal: New England Journal of Medicine (1965)

Presentation of CaseA fifty-nine-year-old retired gardener was admitted to the hospital because of weakness of the legs.Seven years previously ocular pemphigus developed, resulting in severe corneal scarring. Six months before admission there was the onset of a cough productive of sputum, wheezing, exertional dyspnea, anorexia, night sweats and occasional shaking chills. An x-ray film of the chest was interpreted as showing bronchitis, and he was given various medications, including erythromycin, tetracycline, aminophylline, triamcinolone and potassium iodide. The respiratory symptoms subsided within a few months. Two months before admission progressive weakness of the legs began. Soon thereafter a burning . . .